Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer
As the first cyclin-dependent kinases 4 and 6 inhibitors, palbociclib significantly improved the survival of the patients with the hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer. Palbociclib is a crucial landmark in the development history of antineopla...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Chinês |
| Argitaratua: |
Magazine House of Cancer Research on Prevention and Treatment
2022-07-01
|
| Saila: | Zhongliu Fangzhi Yanjiu |
| Gaiak: | |
| Sarrera elektronikoa: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0220 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|